FLOWing with the SemagluTIDE — NephJC
US$ 24.14
tirzepatide for visceral fat How Does Support Weight Management? Visceral Fat vs. Subcutaneous Fat
Description
Risk 5: Loss of Appetite Regulation Poor absorption = unstable appetite control and inconsistent metabolic response
Waiting for full approval and established prescribing guidelines is the prudent path
In clinical trials, tirzepatide produces more weight loss (20-22% at max dose) compared to orforglipron (12.4% at max dose)
These medications can reduce vitamin B12 absorption over time by slowing gastric emptying and altering gut bacteria composition
